Clinical Trial

A Study of Dosing Patterns and Costs in Patients With Spinal Muscular Atrophy Receiving Disease Modifying Therapies

Completed
View on ClinicalTrials.gov →
Summary
The aim of this study was to assess real-world dosing patterns, long-term healthcare costs, and characteristics of SMA patients who received treatment with DMTs. DMTs included onasemnogene abeparvovec, nusinersen, and risdiplam. This study was conducted using both open and closed claims data from the Komodo Health Research Database (KRD+) between 01 January 2016 and 31 October 2024.
Trial Details
NCT Number NCT07378943
Lead Sponsor Novartis Pharmaceuticals
Conditions Muscular Atrophy, Spinal
Enrollment 4,114 participants
Start Date 2024-11-06
Primary Completion 2025-03-30 (estimated)
Study Completion 2025-03-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-30